Inhibition of expression of PODXL with RNAi caused aggregation of the cells. Furthermore, PODXL hi /CD49f hi MSCs were less prone to produce lethal pulmonary emboli, and larger numbers were recovered in heart and kidney after intravenous infusion into mice with myocardial infarcts.
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INTRODUCTION
Among the cells being used for cell therapies for non-hematopoietic tissues are the stem/progenitor cells from bone marrow that were referred to initially as fibroblast colony forming units 1 , subsequently as marrow stromal cells , then as mesenchymal stem cells 2 , and most recently as multipotent mesenchymal stromal cells or MSCs 3 . Clinical trials with MSCs are now in progress [4] [5] [6] [7] [8] [9] , but several questions are still unresolved as to how the cells should be isolated, expanded in culture, and characterized. One view is that confluent cultures of MSCs ( Figure 1A ) are useful and perhaps the optimal preparations for therapy. An opposing view is that confluent cultures of MSCs are partially committed to differentiation or even senescence.
Therefore they lack some of the therapeutic potentials of low density cultures that contain a sub-population of rapidly self-replicating cells [10] [11] [12] , that display a different pattern of expressed genes 13 , that have a greater capacity to generate single-cell derived clones 10, 14 , and that more efficiently engraft in vivo 15 .
MSCs were originally described by Friedenstein et al. 1, 16 who isolated the cells by their ready adherence to tissue culture surfaces, an isolation technique subsequently followed by most investigators 17 . The cells were characterized primarily by their ability to generate colonies in culture and to differentiate into adipocytes, osteoblasts, and chondrocytes.
Numerous attempts were made to develop more specific procedures for isolation and characterization of the cells by preparing antibodies to surface epitopes on MSC. The first was the monoclonal IgM antibody STRO-1 raised against confluent cultures of human MSCs that were used as feeder layers for hematopoietic stem cells 18 . STRO-1 alone or in combination with other antibodies was subsequently employed extensively to identify and isolate MSCs 19- For personal use only. on April 13, 2017. by guest www.bloodjournal.org From 26 . Also, a series of additional monoclonal antibodies were prepared to MSCs [27] [28] [29] [30] . In addition, antibodies initially prepared to other cell types were used to characterize MSCs [31] [32] [33] [34] [35] .
Although the published antibodies to MSCs are useful, none distinguish two major subpopulations that are present in early passage human MSCs plated at low density: (a) spindleshaped and rapidly self-renewing cells referred to as type I cells 12 Recently, we searched for antibodies to surface proteins that identify early progenitors in cultures of MSCs. We found six informative antibodies to proteins that were previously linked to cell trafficking and tumor progression.
MATERIALS AND METHODS (see also Supplemental Materials)
Isolation and culture of human MSCs. MSCs from bone marrow aspirates were obtained from the NIH/National Center for Research Resources (NCRR) funded Tulane Center for the Preparation and Distribution of Adult Stem Cells (http://www.som.tulane.edu/gene_therapy/distribute.shtml). In brief, the MSCs were prepared from 2 to 4 ml bone marrow aspirates of the iliac crest of normal adult volunteers as described previously (see Table S1 and Supplemental Materials) 14, 36 . Passage 1 MSCs from seven different normal donors were used: Donor 1 (#7009), donor 2 (#240L), donor 3 (#5064L), donor 4 (#5068L), donor 5 (#220R), donor 6 (#109L), donor 7 (#5066R), and donor 8 (#281). 
Assays of mRNAs by microarrays.

RESULTS
Microarray assays as a preliminary screen for useful epitopes.
As noted previously 10, 14, 36 , assays by phase contrast microscopy and light scatter demonstrated that MSCs increased in size and complexity when early passage cells were plated at low density and expanded in culture ( Figure 1B and C) . As an initial strategy, we queried microarray data 37 . The yields of cells from 5 day cultures were 3,400 +/-500 S.D. cells/cm 2 (n= 5). Alternatively, the cultures were incubated for 9 day until they were about 90 to 100%
For personal use only. on April 13, 2017. by guest www.bloodjournal.org From confluent, at which point most cells had extensive cell-to-cell contacts and were broader with increased width to length ratios (Figure 1 B ) 10, 12, 36 . The yields of cells varied but were difficult to estimate because the cells readily aggregated (Table 1) . Semi-quantitative RT-PCR assays ( Figure 2A ) confirmed that mRNAs for the six candidate proteins were expressed at higher levels in the 5 day cultures than in the 9 day cultures. The 9 day cultures were then lifted, replated at 100 cells/cm Immunocytochemistry also demonstrated a similar pattern of expression of the six proteins ( Figure 2C ). The proteins were expressed in essentially all Passage 2 cells after incubation for 5 days. After the cells were expanded for 9 days, there was a marked decrease in protein expression. After the 9 day cultures were lifted and re-plated at low density, the proteins were again expressed in most of the cells after 5 days. However, a few cells were negative. After the cultures were expanded for 9 days, most of the cells were negative. Double labeling of day 
Assays of the epitopes on MSCs from different donors.
Because bone marrow aspirates from the iliac crest are taken blindly, there is considerable variation in the number and quality of MSCs that are obtained from aspirates of different donors and aspirates from different sites of the same donor during the same session (see Table S1 ). Also there is considerable variation in the rates at which the cells expand (Table 1) .
To evaluate the variations, Passage 1 MSCs from five different donors were plated at 100 cells/cm 2 and assayed for the four candidate epitopes after the cells were expanded in culture for 5 to 9 days and lifted with trypsin/EDTA (Figures 3 and S2) . Assays for the epitopes by Figure 3D ). GD2
was detected at very low levels in 5 day cultures and the levels increased as the cultures expanded ( Figure 3D ).
Clonogenicity of high and low PODXL/CD49f cells.
Previous observations suggested that the clonogenicity of MSCs cultures decreased as they were expanded toward confluency 11, 49 . To confirm the observation under the culture conditions used here, MSCs were plated at 100 cells/cm 2 . The cultures were expanded for 5
days to obtain MSCs that were PODXL hi /CD49f hi and for 9 days to obtain MSCs that were PODXL lo /CD49f lo . Two sub-populations were then re-plated at 1 cell/cm 2 to assay colony forming units (CFU-Fs). As indicated in Figure 4A 
RNAi for PODXL causes aggregation of MSCs.
PODXL was previously shown to inhibit cell to cell contacts, apparently because its large glucosaminoglycans provide a highly negative charge that shields the receptors for ligand Figure 5D ) and immunocytochemistry ( Figure 5F ).
In contrast, the aggregates expressed much lower levels of mRNA for PODXL ( Figure 5D ).
Also, the antibody to PODXL labeled only the cells on the periphery of the aggregates ( Figure   5 F).
Aggregation of MSCs in suspension.
To assay aggregation of MSCs, Passage 1 cells were expanded for 5 or 9 days to obtain preparation high and low for PODXL and CD4f 
Lethal pulmonary emboli.
To determine whether MSCs produce pulmonary emboli, MSCs were infused into the tail veins of mice. In one series of experiments, mice were infused with increasing concentrations of MSCs cultured for 7 days that were had medium levels of PODXL/CD49f (see Figure 3B ).
The infusions were well tolerated in 10 mice that received infusions of 1 X 10 6 cells that were Figure 6C ) and contained blood vessels with large nucleated cell that appeared to occlude the vessels ( Figure 6D ). The marked tendency to aggregate of MSCs with a knock-down of PODXL (Fig. 5) made them impractical to test with intravenous infusions.
Migration of MSCs to injured myocardium and kidney.
To assess the fate of the MSCs trapped in the lung, DNA and RNA from lungs were assayed 1 day after intravenous infusion of 1 X 10 6 human MSCs. (Fig. 7 B and C) . Therefore the enhanced survival of PODXL hi /CD49f hi MSCs was correlated with increased expression of ezrin together with activation of both MAPK and Akt.
After intravenous infusion human MSCs into the normal mice, assays for Alu sequences indicated that the largest number of cells were detected in the lungs (Fig. 7 A) . The levels of human DNA in other tissues were very low with the highest levels in heart, liver and pancreas E) and produced renal damage as reflected by an increase in serum creatinine levels (0.53+/-0.08 SD vs 1.08 +/-0.14 SD; n = 4). Immunohistochemistry sections revealed a few cells in the border zone of the infarcts that labeled with anti-human nuclei antigen (not shown).
DISCUSSION
By first querying microarray data, we identified a series of mRNAs for surface proteins that were expressed in low passage, low density cultures of MSCs enriched for early progenitor cells but that were not expressed as the cultures expand to confluency. Expression of the surface proteins was established by Western blots and immunocytochemistry. Remarkably, the surface proteins characteristic of early progenitor cells reappeared when sub-confluent cultures were replated at low density. Therefore the results confirmed the plasticity of the cells: If early passage cells are plated at low density, they pass through lag, exponential growth, and near stationary phases 10, 11, 51 . If the cells are replated at low density before they reach confluency, the sequence is repeated through several passages. Commercially available antibodies identified early progenitors in the cultures even after they were lifted by partial Expansion of MSCs at low density to obtain PODXL hi /CD49f hi cells requires larger tissue culture vessels and larger amounts of medium than expansion of confluent cultures ( Figure   1A ). However, 50 to 200 x 10 6 Passage 1 MSCs were readily produced from a single bone marrow aspirate under the conditions described here (Table S1 ). Therefore it should be possible to provide adequate numbers of cells for most clinical trials [6] [7] [8] [9] 63 . Larger numbers of PODXL hi /CD49f hi cells can be obtained by expanding sub-confluent cultures at low density through several passages. However, there is considerable variation among different preparations. Also, it is probably preferable to avoid extensive expansion of the cells that can lead to genomic instability and tumorgenecity as was observed after prolonged culture of both human MSCs 70 Figure 1 For personal use only. on April 13, 2017. by guest www.bloodjournal.org From Figure 2 For personal use only. on April 13, 2017. by guest www.bloodjournal.org From Figure 3 For personal use only. on April 13, 2017. by guest www.bloodjournal.org From Figure 4 For personal use only. on April 13, 2017. by guest www.bloodjournal.org From Figure 5 For personal use only. on April 13, 2017. by guest www.bloodjournal.org From Figure 6 For personal use only. on April 13, 2017. by guest www.bloodjournal.org From Figure 7 For personal use only. on April 13, 2017. by guest www.bloodjournal.org From
